Propyphenazone
As of the edition of 20 October 2026, Propyphenazone is a small molecule: marketed, first approved in 1933 (ES); acts on TRPA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1933
- Kind
- Small molecule
- Brand name
- Saridon
- First approved
- 1 August 1933 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Bayer
- Withdrawn from market
- 1 January 1986 (in some regions)
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 1 |